**Introduction**

Neuroendocrine tumors (NETs) arise both in the gastro-entero-pancreatic tract and in the bronchopulmonary (BP) system ([Figure 1](#)) (1). BP NETs comprise a spectrum of tumors that specifically arise from respiratory neuroendocrine cells. They represent ~20% of all lung neoplasia and ~30% of all NETs (2). BP-NETs may present with cough, hemoptysis, and obstructive pneumonia but this depends on their site, size, and growth pattern. They are frequently identified serendipitously on chest radiology. Less than 5% exhibit hormonally-related symptoms such as carcinoid syndrome, Cushing, acromegaly, or SIADH.

BP-NETs are divided into four subgroups: typical carcinoid tumor (TC), atypical carcinoid tumor (AC), large-cell neuroendocrine carcinoma (LCNEC), and small-cell...
lung carcinoma (SCLC). Both SCLC and LCNEC progress rapidly, are aggressively metastatic, with a poor prognosis. TC generally behaves in a benign/indolent fashion, whereas AC exhibit indolent to highly aggressive behavior. SCLC is the most common variant, whereas LCNEC is the rarest. The only curative treatment is surgical resection. TC exhibits a fairly good prognosis (5-year survival, ~90%), although metastases may appear years after apparently radical resection of the primary. The 5-year survival of AC is 50–80% consistent with a more aggressive phenotype. The highly malignant LCNEC and SCLC exhibit poorer prognoses, 30% and <5%, respectively\(^\text{(2,3)}\).

Given the widely different biological behavior between different types of BP-NETs, and the development of liver metastases, treatment is mostly focused on either the removal of the primary lesion or the management of metastatic disease. Ideally, removal of the primary tumor should be initially undertaken and thereafter, appropriate strategies developed for the management of residual disease. This is usually undertaken in a multidisciplinary fashion and is individualized according to the histological type e.g., TC or AC and burden, as well as symptomatology. For unresectable tumors, optimal selection of palliative treatment options (timing and modality) is of paramount importance to maintain or improve quality of life (QoL) and prolong overall survival (Figure 2).

The surgical options include resection of the primary (wedge resection or lobectomy, and in extreme cases pneumonectomy), hepatic resection of metastases, radiofrequency ablation, stereotactic body radiation therapy (SBRT) and even hepatic transplantation (4,5). Interventional radiology techniques include embolization of hepatic metastases (with or without cytotoxic agents) or the use of radioactive microspheres. Medical therapy ranges from the use of bioactive agents such as somatostatin analogs or interferon to standard chemotherapy. More recently, a variety of novel molecular targeted agents including the mTOR inhibitor Everolimus have been utilized with marginal efficacy (3). Among chemotherapeutic agents, temozolomide has been tested in several non-randomized trials, alone or in combination with targeted therapies in patients with well- and intermediately differentiated BP-NETs with some activity (6). Of particular interest has been the development of targeted radiotherapy using a variety of different isotopes including Indium, Yttrium and Lutetium (7). This novel therapeutic strategy, delivered by intravenous infusion has been designated peptide receptor radionuclide therapy (PRRT).

**PRRT background**

PRRT with radiolabeled somatostatin analogs is an innovative treatment for inoperable or metastasized, well/moderately differentiated, NETs (7). Initially developed for gastroenteropancreatic tumors, it is also used in BP-NET because these tumors express the target receptor (8). Radiolabeled somatostatin analogs represent, to date, the prototype and the most successful paradigm of theranostics, namely of molecules exploiting the same receptor binding and internalization mechanism for imaging and therapy. This reflects the development of the synthetic somatostatin analog peptides, which are octreotide and the variety of radio-labelled variants. The therapeutic efficacy is related to a high affinity for somatostatin receptors subtype 2 (sst2) and moderate affinity for subtype 5 (sst5). A high proportion (67%) of bronchial NETs over-express somatostatin receptors, especially the sst2 subtype (9).

Binding of an isotopically labeled radiopeptide to somatostatin receptors expressed on the cell membrane of NET results in internalization and delivery of the radioactivity directly into the intracellular space of the tumor cell (Figure 3). This retention of intracellular radiation is associated with DNA damage through beta-emission and subsequent apoptosis through an inability of
the cell to correct the damage. Other internal structures including mitochondria may be destroyed by radiation.

Clinically, PRRT comprises the systemic administration of a suitably radiolabeled synthetic somatostatin analog, fractionated into sequential cycles (usually 4–5) every 6 to 9 weeks, until the intended total amount of radioactivity has been delivered. The precise amount administered is dependent on the limitations imposed by renal irradiation and, to a lesser extent, bone marrow sensitivity.

PRRT was introduced into clinical practice in 1994. This was the logical theranostic application following the development of diagnostic techniques for localization of NET using the radiolabeled somatostatin analog \(^{111}\text{In-DTPA0-D-Phe1}\)-octreotide or \(^{111}\text{In-pentetreotide}\) (10). Using the same principle, but with an increased isotope activity (high-dose \(^{111}\text{In-pentetreotide}\)), a theranostic was developed. Therapeutic efficacy was linked to the activity of the Auger and conversion electrons emitted by \(^{111}\text{Indium}\) (low) and consequently disease remission was rare (11). This led to the use of isotopes with higher energy and longer range, such as the pure beta emitter \(^{90}\text{Yttrium}\). The particles

Figure 2: Treatment options in bronchopulmonary NETs (typical and atypical carcinoids). In metastatic or unresectable disease loco-regional strategies as well as systemic treatments, such as PRRT, are performed. PRRT, peptide receptor radionuclide therapy; NET, neuroendocrine tumor; STZ, streptozotocin; TMZ, temozolomide; SSA, somatostatin analog; EVE, everolimus; IFN, interferon.

Figure 3: Mechanism of effectiveness of PRRT. After the somatostatin (SS) analog linked to the isotope binds to the membrane somatostatin receptor, the radiopeptide/somatostatin receptor complex is internalized. Thus, radioactivity is transported into the intracellular receptor recycling compartment of the NET cell where it exerts its action in proximity to the nucleus. PRRT, peptide receptor radionuclide therapy.
emitted by $^{90}$Y (maximum energy 2.27 MeV, penetration range $R_{\beta_{\text{max}}}$ 11 mm, half-life $T_{1/2}$ 64 hrs) allowed for a direct killing of somatostatin receptor-positive cells and a cross-fire effect that targeted nearby receptor-negative tumor cells. Novel octreotide analogs were also developed to increase efficacy. For $^{90}$Y, a new analog, Tyr$^3$-octreotide, with a similar pattern of affinity for somatostatin receptors, was developed at the University of Basel. This analog was characterized by high hydrophobicity, ease of labeling with $^{111}$In and $^{90}$Y, and tight binding to the bifunctional chelator DOTA, which securely encloses the radioisotope (1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetra-acetic acid)(12,13).

($^{90}$Y-DOTA$^0$,Tyr$^1$)-octreotide or $^{90}$Y-DOTATOC or $^{90}$Y-octreotide was initially used in the treatment of metastatic NETs in 1996 (7). The excellent symptomatic and objective response following several cycles of $^{90}$Y-octreotide therapy encouraged further studies to examine the potential of PRRT in NET disease (14). As a consequence, $^{90}$Y-octreotide became the most utilized radiopeptide in the first decade of PRRT experience (15-19).

Since 2000, a more effective analog, octreotate (Tyr$^8$, Thr$^8$-octreotide) with 6- to 9-fold higher affinity for sst2, was developed and clinically utilized. The chelated analog (DOTA)$^5$-Tyr$^8$-octreotate or DOTATATE can be labeled with the $\beta$-$\gamma$ emitter Lutetium-177 ($E_{\text{max}}$ 0.49 MeV, $R_{\text{max}}$ 2 mm, $T_{1/2}$ 6.7 days) and has been investigated in several clinical phase I and II studies (15,20,21). $^{177}$Lu-octreotate has subsequently become one of the most frequently utilized radiopeptides for PRRT. This has been particularly evident in recent studies given its efficacy, tolerability and manageability (22,23). $^{177}$Lu-octreotate has recently being evaluated in a randomized phase III registration trial in small bowel NET.

**PRRT clinical protocol**

Candidates for PRRT are individuals with tumors exhibiting a significant over-expression of somatostatin receptors. Inclusion criteria also include the functionality of somatostatin receptors, namely their ability to internalize the receptor-analog complex and retain the radioactivity inside the cell.

Individuals are selected based on the results of scintigraphy with $^{111}$In-pentetreotide (or, more recently, receptor PET with $^{68}$Gallium-labeled octreotide). Appropriate candidates have image results indicative of adequate uptake (at least equal to the uptake of normal liver) as evidence of targetable somatostatin receptors. This is necessary to ensure and calculate an appropriate high tumor dose with low exposure to normal tissues that express physiological levels of somatostatin receptors (24).

Scintigraphic or PET tomoscintigraphic evaluation is the most accurate noninvasive method to identify and confirm the over-expression of functioning receptors (25). Optimally, as opposed to immunohistochemistry determination, the use of in vivo functional scintigraphic
or PET methods facilitates the simultaneous evaluation of the receptor density and the internalization capacity in real time in all lesions, which is useful for therapeutic selection of patients (Figure 4).

When evaluating images to determine PRRT selection, it is important to exclude false positives. False positives include uptake in the gall bladder (inflammation), accessory spleens, recent surgical scars (inflammatory infiltrate), previous radiotherapy and any other cause of granulomatous-lymphoid infiltrate that can mimic the presence of NET tissue. The signal typically represents accumulation of inflammatory cells which express somatostatin receptors.

False negatives should also be considered. These are mainly represented by small, sub-centimeter lesions, below the resolution limit of the instrument (although this limitation is partially overcome by receptor PET/CT). In addition, certain tumors, such as the majority of highly malignant and high grade (Ki67 >55%) NETs do not express adequate numbers of detectable somatostatin receptors.

PRRT technique

PRRT consists of the systemic administration of a radiolabeled somatostatin analog. The radiopeptide is intravenously administered slowly over 20–30 minutes in approximately 100 mL of saline. The cumulative activity, fractionated in multiple cycles, is calculated from imaging results to efficiently irradiate the tumor, without surpassing the tolerance dose threshold of the kidneys and bone marrow, in an individualized fashion. The timing of fractionation, every 6 to 9 weeks, is based upon calculations regarding recovery times from possible acute hematological toxicity (7).

To diminish renal dose of irradiation, patients are premedicated with an intravenous infusion of positively charged amino acids (lysine or arginine) in the amount of ~25 g per day. This infusion is initiated 30–60 minutes prior to the administration of the isotope and is maintained until 2–3 hours following cessation of the isotope infusion. The infusion both hydrates the patients and reduces the renal radioactivity dose by competitively inhibiting the proximal tubular reabsorption of the radiopeptide. In some circumstances, mild adverse events are experienced. These include gastro-intestinal symptoms such as a slight nausea, and occasionally emesis. These may be related to the amino acid co-administration, but are easily controlled with appropriate medication.

PRRT efficacy

Two decades of clinical application with either ⁹⁰Y-octreotide or ¹⁷⁷Lu-octreotate, has demonstrated PRRT is an effective clinical therapy as measured by tumor response, symptom relief and QoL improvement (Table 1). The recent NETTER-1 phase III randomized trial of ¹⁷⁷Lu-DOTATATE vs. high-dose Octreotide LAR in patients with inoperable, progressive, midgut carcinoid tumors identified that ¹⁷⁷Lu-octreotate significantly improves PFS (PFS not reached vs. 8.4 months; hazard ratio 0.21, with a 79% reduction of the risk of progression) (33). The overall number of deaths was also significantly lower in the PRRT group (14 vs. 26).

PRRT and BP NET

Three recent studies have examined the utility of PRRT in BP-NETs. In the first, a phase II study that was performed in individuals with “poor responding” tumors including bronchial and gastric NECs. Patients were treated with standard 22.2–29.6 GBq activities. The results for BP-NETs were: 5 partial responses, 1 minor response and 2 stabilizations in nine patients. In this series, PRRT was as effective in bronchial NETs as had been noted in GEP-NETs (34).

In a recent, larger study (n=34 bronchial NETs), the disease control rate was 80%, with 6% achieving a complete response, 27% a partial response and 47% disease stabilization. The overall median progression-free survival (mPFS) was 20.1 months (95% CI: 11.8–26.8 months) for the group. Interestingly, the mPFS was shorter in patients with positive TTF-1 (thyroid transcription factor 1: n=18; 7.2 vs. 26.3 months). This reflects a more aggressive pattern. In addition, a positive FDG PET/CT (n=16), which is reflective of more metabolically active and aggressive disease was also associated with a shorter mPFS (15.3 vs. 26.4 months) (35).

A retrospective review of 114 advanced bronchial NETs treated with ⁹⁰Yttrium-, a combination of ⁹⁰Y and ¹⁷⁷Lu-Lutetium-, or ¹⁷⁷Lu-based PRRT protocols at IEO Milan, identified the median overall survival to be 58.8 months, with an mPFS of 28 months. Patients treated with ¹⁷⁷Lu-DOTATATE, alone or in combination with ⁹⁰Y-PRRT (n=48 and 21, respectively) exhibited the longest 5-year overall survival (61.4% for both series, vs. 31.6% for ⁹⁰Y-PRRT). No factor clinical factor(s) was identified that could accurately measure efficacy of therapy in BP-NETs or predict those patients who would benefit from PRRT (36).
### Table 1 Clinical results of PRRT with either $^{90}$Y-octreotide or $^{177}$Lu-octreotate in GEP NETs

<table>
<thead>
<tr>
<th>Agent</th>
<th>Schedule</th>
<th>Patients</th>
<th>CR</th>
<th>PR</th>
<th>DCR</th>
<th>Progression at baseline</th>
<th>Response criteria</th>
<th>Outcome (median PFS or TTP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$^{90}$Y-octreotide</td>
<td>7.4 GBq/sqm in 4 cycles (26)</td>
<td>36 GEP</td>
<td>4%</td>
<td>20%</td>
<td>92%</td>
<td>100%</td>
<td>WHO</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>2.96–5.55 GBq/cycle $\times$ 2 (16)</td>
<td>21 GEP</td>
<td>0%</td>
<td>28%</td>
<td>71%</td>
<td>NA</td>
<td>WHO</td>
<td>TTP 10 m</td>
</tr>
<tr>
<td></td>
<td>0.93–2.78 GB/sqm/cycle (27)</td>
<td>58 GEP</td>
<td>0%</td>
<td>9%</td>
<td>71%</td>
<td>81%</td>
<td>SWOG</td>
<td>TTP 29 m</td>
</tr>
<tr>
<td></td>
<td>4.4 GBq/cycle $\times$ 3 (18)</td>
<td>90 SI</td>
<td>0%</td>
<td>4%</td>
<td>74.4%</td>
<td>100%</td>
<td>SWOG</td>
<td>PFS 16 m</td>
</tr>
<tr>
<td></td>
<td>1–10 cycles (median 2), various activity (19)</td>
<td>821 GEP</td>
<td>0.2%</td>
<td>38%</td>
<td>NA</td>
<td>NA</td>
<td>RECIST</td>
<td>NA</td>
</tr>
<tr>
<td>$^{177}$Lu-octreotate</td>
<td>27.8–29.6 GBq in 3–4 cycles (20)</td>
<td>310 GEP</td>
<td>2%</td>
<td>28%</td>
<td>81%</td>
<td>43%</td>
<td>SWOG</td>
<td>PFS 33 months</td>
</tr>
<tr>
<td></td>
<td>3.7–29.2 GBq in 4–6 cycles of 3.7–7.4 GBq (21)</td>
<td>39 GEP</td>
<td>3%</td>
<td>31%</td>
<td>88%</td>
<td>76%</td>
<td>RECIST</td>
<td>TTP 36 months</td>
</tr>
<tr>
<td>Mean 25.5 GBq in 5 cycles, normal subjects; mean 17.8 GBq in risk patients (28)</td>
<td>52 P</td>
<td>8%</td>
<td>21%</td>
<td>81%</td>
<td>88%</td>
<td>SWOG</td>
<td>PFS 20 months in reduced dosage, not reached in full dosage</td>
<td></td>
</tr>
<tr>
<td></td>
<td>32 GBq in 4 cycles (29)</td>
<td>68 P</td>
<td>0%</td>
<td>60.3%</td>
<td>85.3%</td>
<td>67.6%</td>
<td>SWOG</td>
<td>PFS 34 months</td>
</tr>
<tr>
<td>Median 25.7 vs. 18.4 GBq (normal vs. risk patients) (30)</td>
<td>43 SI</td>
<td>7%</td>
<td>0%</td>
<td>84%</td>
<td>100%</td>
<td>SWOG</td>
<td>PFS 36 months</td>
<td></td>
</tr>
<tr>
<td></td>
<td>32 GBq in 4 cycles (31)</td>
<td>61 SI</td>
<td>0%</td>
<td>13.1%</td>
<td>91.8%</td>
<td>75.4%</td>
<td>SWOG</td>
<td>PFS 33 months</td>
</tr>
<tr>
<td>27.8–29.6 GBq in 3–4 cycles vs. octreotide LAR 60 mg/month (32)</td>
<td>201 SI</td>
<td>19% (Lu) vs. 3% (LAR) CR + PR</td>
<td>20% (Lu) vs. 58% (LAR)</td>
<td>100%</td>
<td>RECIST</td>
<td>PFS not reached (Lu) vs. 8.4 months (LAR)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PRRT, peptide receptor radionuclide therapy; GEP, gastroenteropancreatic; NET, neuroendocrine tumor; CR, complete response; PR, partial response; DCR, disease control rate; SI, small intestine; Lu, lutetium; LAR, long-acting release; PFS, progression-free survival; TTP, time to progression; NA, not assessed.

### Efficacy of individual peptides

#### $^{90}$Y-octreotide

Information regarding $^{90}$Y efficacy in BPNETs is difficult to evaluate at this time as the original studies were heterogeneous in composition. Nevertheless, some observations can be made.

In a study carried out at Basel University, 39 patients with NETs, mostly of GEP origin, were treated with 4 cycles of $^{90}$Y-octreotide, with a cumulative activity of 7.4 GBq. Three patients with progressive bronchial tumors were included. All demonstrated disease stabilization after PRRT (37). The group as a whole had 2 complete remissions, 7 partial responses and 27 disease stabilization.
The results of two phase I–II studies and a retrospective evaluation in 141 patients were published by the Milan group in 2004 (38). NETs, principally of the gastro-entero-pancreatic (n=58; 41.1%) and bronchial tract (n=12; 8.5%) were treated with a cumulative activity of 7.4–26.4 GBq of $^{90}$Y-octreotide, divided into 2–16 cycles, administered 4–6 weeks apart. In the 11 patients with bronchial tumors, 10 (91%) were in progression at enrolment, and were treated with standard courses of PRRT, with cumulative activities ranging from 8 to 22.5 GBq. After completion of the treatment, 1 patient had a partial remission and 8 showed stabilization of disease (SWOG criteria). In an earlier escalation study published by the same group in patients with somatostatin positive tumors (mainly in progression), 3 patients with bronchial NETs were included, with resulting stability and partial remission in 2 (17).

More recently, the Basel group published the results of an open-label phase II trial in 1,109 patients treated with $^{90}$Y-octreotide, divided into multiple cycles of 3.7 GBq/m$^2$ each. In this series, 84 bronchial NET were treated. The rate of objective response was 28.6%. This was similar to small bowel NET (26.8%) but less than for pancreatic NET (47%). The best predictor of survival, however, was the tumor uptake at baseline (19).

90$Y$- + 177Lu-peptide combinations

Protocols combining 177Lu- and 90Y-peptides have been recently considered in order to take advantage of the different physical properties of both two radionuclides. Theoretically, the combination of the two radioisotopes should allow simultaneous treatment of large lesions (based on the higher energy and penetration range of the particles emitted by 90Y) as well as on small lesions (based on the lower energy and penetration range of 177Lu). The results of PRRT performed in a Danish cohort of 69 patients treated in Basel with different combinations of Y- and/or Lu-peptides were recently published. Six patients with bronchial NETs were included; 1 exhibited a partial remission and 3 exhibited stabilization (39).

177Lu-octreotate

177Lu-DOTATATE or 177Lu-octreotate is currently the most commonly used radiopeptide for PRRT. It has a higher affinity for the somatostatin sst2 receptor, it is easier to use, it results in a lower dosimetric burden on the kidney because of lower radiation, and it allows radiologists to obtain scintigraphic images and undertake dosimetric studies at the same time, owing to the gamma photon co-emission of 177Lu.

A cohort of 51 patients with unrectable/metastatic NETs, 5 of which of BP origin, were treated in a phase I–II study in Milan aimed at defining toxicity and efficacy of 177Lu-octreotate. Patients were divided into two groups, receiving escalating activities, from 3.7–5.18 GBq and from 5.18–7.4 GBq, with cumulative activities up to 29 GBq, based on dosimetry. Partial and complete responses were observed in 15 patients (32.6%) (21).

A salvage protocol with 177Lu-octreotate was published by the Rotterdam group. Patients in progression were enrolled after an initial response to PRRT with 177Lu-octreotate, administered using standard cumulative activities (22.2–29.6 GBq). In this series, 32 patients with bronchial or GEP-NETs received 2 additional cycles of 177Lu-octreotate, with a cumulative activity of 15 GBq. Nevertheless, this “salvage therapy” was well tolerated by the majority of patients and should be considered as a valuable option for subjects who exhibit progression on PRRT (40).

PRRT safety profile

Accumulated clinical experience and evidence accumulated over the past two decades and have demonstrated that PRRT with 90Y- and 177Lu-peptides is generally well-tolerated and that adverse events are modest. Acute side effects are usually mild (nausea and rarely, emesis) and are correlated to the (type of) co-administration of amino acids used to reduce renal exposure to radiation. Other adverse modest events (commonly, fatigue) and the exacerbation of an endocrine syndrome or hormonal crisis (~1%, mainly occurring in the treatment of functional tumors) represent the cytotoxic effects of the radiopeptide. Chronic and permanent effects in the kidneys and the bone marrow are generally mild if the necessary precautions (renal protection with amino acids; dosage fractionation and attention to specific risk factors e.g., hypertension or previous nephro- or myelo-toxic chemotherapy regimens), are undertaken (24,41) (Table 2).

Usage of appropriate dosimetry improves the delivery of elevated absorbed doses to the tumor, with relative sparing of healthy organs (kidneys, bone marrow) (45) (Table 3).

Renal

Renal irradiation occurs due to the reabsorption of the
radio peptides in the proximal convoluted tubules, with a subsequent accumulation in the renal interstitium, where the radioactivity exerts its action inducing vasculitis and fibrosis (47). Renal toxicity is significantly decreased when positively charged amino acids, such as lysine and arginine, are co-infused with the radioligand. These competitively inhibit proximal tubular radiopeptide reabsorption by saturating the apical membrane megalin, resulting in a 9–53% reduction in renal radioactive dosage (48). Overall, a mild loss of renal function does occur over time, with a median decline in creatinine clearance of 7.3% per year for \( ^{90} \text{Y-octreotide} \) and 3.8% per year for \( ^{177} \text{Lu-octreotate} \) (49). Severe, end-stage renal damage, however, remains rare with \( ^{177} \text{Lu-octreotate} \) and only sporadic cases are reported in literature (15). Earlier concerns of high numbers of renal problems reported were mostly associated with the use of \( ^{90} \text{Y-peptide PRRT} \), and reflected administration of very high activities in the absence of amino acid induced renal protection or renal protection with low/nihil lysine and arginine amounts (50).

Overall PRRT with \( ^{90} \text{Y-peptides} \) is more frequently associated with a reduction of renal function, presumably reflecting the specific physical characteristics of the \( ^{90} \text{Y} \) radionuclide, namely the much larger particle penetration into the kidney. A long-term evaluation of renal toxicity in a group (n=28) undergoing PRRT with dosimetric analysis showed that, of the 23 treated with \( ^{90} \text{Y-octreotide} \), a lower dose threshold for toxicity was observed in patients with risk factors (mainly hypertension and diabetes) (51). In a retrospective series (n=1,109) treated with

<table>
<thead>
<tr>
<th>Agent</th>
<th>Patients</th>
<th>Follow-up (months)</th>
<th>Renal toxicity</th>
<th>MDS</th>
<th>Acute leukemia</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>( ^{90} \text{Y-octreotide} )</td>
<td>40</td>
<td>19</td>
<td>10% Grade 1</td>
<td>0</td>
<td>0</td>
<td>(16)</td>
</tr>
<tr>
<td></td>
<td>39</td>
<td>6</td>
<td>3% Grade 2</td>
<td>0</td>
<td>0</td>
<td>(26)</td>
</tr>
<tr>
<td></td>
<td>58</td>
<td>18</td>
<td>3% Grade 4</td>
<td>1</td>
<td>0</td>
<td>(27)</td>
</tr>
<tr>
<td></td>
<td>1,109</td>
<td>23</td>
<td>9.2% Grade 3/4</td>
<td>1</td>
<td>1</td>
<td>(19)</td>
</tr>
<tr>
<td></td>
<td>358</td>
<td>30</td>
<td>2.8%</td>
<td>7 (1.95%)</td>
<td>5 (1.4%)</td>
<td>(42)</td>
</tr>
<tr>
<td>( ^{177} \text{Lu-octreotate} )</td>
<td>504</td>
<td>19</td>
<td>0.4% Grade 4</td>
<td>3</td>
<td>0</td>
<td>(20)</td>
</tr>
<tr>
<td></td>
<td>51</td>
<td>29</td>
<td>24% Grade 1</td>
<td>0</td>
<td>0</td>
<td>(21)</td>
</tr>
<tr>
<td></td>
<td>74</td>
<td>21</td>
<td>1.3% Grade 3/4</td>
<td>3</td>
<td>0</td>
<td>(43,44)</td>
</tr>
<tr>
<td></td>
<td>290</td>
<td>30</td>
<td>0%</td>
<td>6 (2.06%)</td>
<td>2 (0.69%)</td>
<td>(42)</td>
</tr>
</tbody>
</table>

PRRT, peptide receptor radionuclide therapy; GEP-NET, gastroenteropancreatic neuroendocrine tumor; MDS, myelodysplastic syndrome.

| Table 3 Mean absorbed doses for \( ^{90} \text{Y-octreotide} \) and \( ^{177} \text{Lu-octreotate} \) |
|-----------------------------------------------|-----------------------------------------------|
| Organ                                        | \( ^{90} \text{Y-octreotide} \) | \( ^{177} \text{Lu-octreotate} \) |
| Mean (Gy/GBq) 13 GBq course (Gy)             | Mean (Gy/GBq) 29 GBq course (Gy)             |
| Kidney*                                       | 1.1–5.1                                       | 0.3–1.7                                        |
| Bone marrow                                   | 0.02–0.2                                      | 0.01–0.08                                      |
| Tumor                                         | 1.4–42                                        | 0.6–56                                        |

Data derived from published studies (46) (with examples of standard full courses of therapy, using either 13 or 29 GBq). In general, absorbed doses to normal organs, e.g., kidney or bone marrow, are variable on an individual basis. Specific tumor absorbed doses are dependent on the level of radioactivity concentration in individual lesions, and increase with radioactivity accumulation in the tumor. Tumor doses themselves are also highly variable based upon factors intrinsic to the tumor itself, particularly the density of somatostatin receptors on the tumor cell membranes, the dimension of the lesions and the distribution of radioactivity within the lesions. *, renal doses are calculated based upon the use of renal protection with amino acid solutions.
multivariate regression revealed that the initial kidney uptake was predictive of severe renal toxicity. However, it seems likely that this relatively high incidence was related to the high-administered activities per cycle (3.7 GBq/m² body surface, namely activities of about 6.4 GBq per cycle in a standard male). Furthermore, individuals with pre-existing impairment of renal function were not excluded from PRRT and infusion of protective amino acids was not routinely employed in the earlier phases of the study (50).

Recently, the results of an analysis of long-term tolerability of PRRT (n=807) treated with ⁹⁰Y-octreotide, ¹⁷⁷Lu-octreotate or the combination (Lu: 34.4%, Y: 44.4%, Lu + Y: 19.5%) provided additional information regarding PRRT toxicity. This analysis illuminated the lack of a clearly definable role for previous clinical parameters (such as diabetes, hypertension and chemotherapy) considered responsible. Nephrotoxicity, either transient or persistent, occurred in 279 (34.6%); this was severe in 1.5%. ⁹⁰Y-peptides or the combination of ⁹⁰Y/¹⁷⁷Lu-peptides showed greater G3/G4 nephrotoxicity (2.8% and 1.3%, respectively) than ¹⁷⁷Lu-peptides alone (0%). However, less than 30% of risk for toxicity could be modeled by clinical parameters. Hypertension and anemia were noted to be the most relevant known risk factors. It seems probable that a unique individual susceptibility to toxicity, possibly of genetic origin, might play a role (42).

**Hematological**

From a hematological perspective, PRRT is generally well-tolerated. Subacute toxicity with severe WHO grade 3 or 4 toxicity occurs in <13% after ⁹⁰Y-octreotide and in ~10% after ¹⁷⁷Lu-octreotate. Nevertheless, sporadic cases of myelodysplastic syndrome (MDS) or even overt acute leukemia have been reported, in the order of 2% (41). Although predicted absorbed doses are lower than the conventional threshold for toxicity, both acute and permanent bone marrow damage remains a cause for concern, particularly in the event of repeated radionuclide administrations or heavy pretreatment with chemotherapy (52).

An analysis of 203 patients treated with 4 intended cycles of 8 GBq each at 3-month intervals, had an incidence of MDS of 1.4%. Myelo-suppression was almost invariably reversible and the cumulative administered activity and initial cytopenia were the most important risk factors for myelotoxicity (43).

The analysis of the 807 group identified that MDS occurred in 2.35% (42). The “classical” risk factors, such as chemotherapy were only associated with predicting risk of toxicity in 30%. Clinical features, such as platelet toxicity grade and the increasing duration of PRRT, were, partially responsible. This led to speculation that unidentified individual genetic susceptibilities, may be related to developing radiation-associated disease (42).

More recent studies have demonstrated that ¹⁷⁷Lu-octreotate can be safely utilized even in florid bone metastases, with extreme bone replacement and the potentially higher exposure of bone marrow (53). Significant G3/G4 reversible hematological toxicity occurred in 35% (n=4) of 11 patients. Toxicity either resolved spontaneously (1 case) or was controlled by support therapy (3 cases). A return to baseline values was obtained in 23 months after completion of PRRT (53).

Finally, the issue of a potential increased toxicity of Everolimus, a bioactive drug frequently used in BP NETs, when administered after the completion of PRRT, has been examined in two studies (54,55). This is important because everolimus has well described adverse effects, and the question is whether the combination therapy would yield a cumulative increase in toxicity. In a prospective study 24 subjects pretreated with PRRT had no significant adjunctive toxicity when treated with Everolimus, compared to the non-PRRT treated individuals from the literature (e.g., RADIANT-3 study). Major events were hyperglycemia (20.8%), fatigue (8.3%), thrombocytopenia (8.3%) and elevated ALT (8.3%) (54). These results differ to a retrospective multicentric study which indicated higher severe toxicity in patients previously treated with systemic chemotherapy and PRRT. This issue is incompletely resolved, due to the lack of robust prospective data, but remains of considerable clinical significance given the increasingly frequent use of sequential multidisciplinary strategies employing both treatments (55).

**Future advances**

A requirement to define the efficacy of PRRT is the need to more scientifically assess the parameters of response to the treatment. Specific molecular features including the identification of tumor radiation sensitivity markers, identification of lung-specific markers to quantify proliferation and apoptosis and easily accessibly molecular indices e.g., circulating tumor biomarkers...
that define response need delineation. Such information would augment and perhaps supplant the current tools such as image-based evidence of disease extension, quantification of basal isotope uptake at receptor imaging and the pathological and morphological assessments of the lesion type.

Some steps have already been undertaken. Pre-treatment functional analysis of tumors utilizing metabolomic parameters conveys information in regard to the likelihood of radiation sensitivity (56). Recent studies have noted that FDG is a crucial parameter in predicting the duration of response to PRRT including in BP-NETs. Individuals with positive FDG exhibit a significantly shorter PFS, clear evidence that tumor glucose utilization represents a significant parameter in predicting therapeutic efficacy (57).

In a reality where prediction of outcome (efficacy, tolerability) becomes a major issue, in view of the multidisciplinary sequencing of long and expensive therapies, and where both conventional (morphologic/functional) imaging and current biomarkers have demonstrated their limitations (Figure 5). As adjunct, molecular tools, such as transcript analysis of specific circulating NET mRNA signature have begun to show promising results. A circulating multianalyte 51-gene NET signature demonstrated significant advantage in early detection of residual disease of surgery-treated patient or in the assessment of somatostatin analog response (58,59). Furthermore, this tool can accurately define and predict response to PRRT including in BPNET (60).

**Conclusions**

PRRT has become a well-accepted effective therapeutic modality for inoperable or metastatic GEP and now has an established role in the treatment of BP-NET. It is overall well-tolerated with the majority of recipients experiencing only moderate toxicity if the necessary precautions are undertaken. The two most commonly used radiopeptides, $^{90}$Y-octreotide and $^{177}$Lu-octreotate, produce significant objective response rates, with positive impact on PFS and OS. In addition, both biochemical and symptomatic responses are commonly observed. Sophisticated molecular tools need to be incorporated into the management strategy to more effectively define therapeutic efficacy and early identification of adverse events. The strategy of randomized controlled trials is a key issue to standardize the treatment and establish the position of PRRT in the therapeutic algorithm of BP-NETs.

**Acknowledgements**

None.

**Footnote**

Conflicts of Interest: The authors have no conflicts of interest to declare.

**References**

1.  Modlin IM, Oberg K, Chung DC, et al.


